Affimed Appoints Dr. Wolfgang Fischer as Chief Operating Officer
September 13 2017 - 5:02AM
Heidelberg, Germany, September 13, 2017 - Affimed N.V. (Nasdaq:
AFMD), a clinical stage biopharmaceutical company focused on
discovering and developing highly targeted cancer immunotherapies,
announced today the appointment of Dr. Wolfgang Fischer as Chief
Operating Officer.
"We are very pleased that Dr. Wolfgang Fischer
has joined our management team as COO," said Dr. Adi Hoess, Chief
Executive Officer of Affimed. "With his solid track record in drug
development and project management as well as his strong immunology
and oncology background, Wolfgang's expertise will support the
Company as we continue to advance our unique immune cell engagers
through clinical development."
Dr. Fischer brings to Affimed 20 years of
experience in research and drug development with a focus on
oncology, immunology and pharmacology. He joins the Company from
Sandoz Biopharmaceuticals (Novartis Group), where he managed the
development and registration of Sandoz' biosimilar pipeline assets
since 2012 and served as Global Head of Program and Project
Management since 2014. Prior to joining Sandoz, he held various
positions of increasing responsibility within the Novartis Group
since 2003, including Medical Director Oncology for Novartis Pharma
Switzerland AG as well as Regional Medical Director Hematology
(Emerging Growth Markets), where he was responsible for the
Hematology Medical Affairs program and supported the launch of
several products in various countries.
"Affimed's strong technology base and growing
pipeline of tetravalent bispecific antibodies have made the Company
a leader in immune cell engagement, particularly in NK cell-based
immunotherapy," said Dr. Wolfgang Fischer. "I am excited to join
Affimed's team, which has generated a number of uniquely positioned
clinical and pre-clinical product candidates. I am fully committed
to contributing to Affimed's success as we continue to address the
existing medical need in hematologic and solid tumor
indications."
Dr. Wolfgang Fischer holds a Ph.D. in Cancer
Research from the Swiss Federal Institute of Technology (ETH),
Zurich, Switzerland. Thereafter, he completed postdoctoral
fellowships at the Swiss Institute of Experimental Cancer Research,
Lausanne, Switzerland and at the Scripps Research Institute,
Department of Immunology, La Jolla, CA, USA, followed by a state
doctorate (Habilitation) in Pharmacology and Toxicology at the
Medical School of the University of Wuerzburg in Germany in
2003.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted
immunotherapies, seeking to cure patients by harnessing the power
of innate and adaptive immunity (NK and T cells). We are developing
single and combination therapies to treat cancers and other
life-threatening diseases. For more information, please visit
www.affimed.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar
expressions. Forward-looking statements appear in a number of
places throughout this release and include statements regarding our
intentions, beliefs, projections, outlook, analyses and current
expectations concerning, among other things, our ongoing and
planned preclinical development and clinical trials, our
collaborations and development of our products in combination with
other therapies, the timing of and our ability to make regulatory
filings and obtain and maintain regulatory approvals for our
product candidates our intellectual property position, our
collaboration activities, our ability to develop commercial
functions, expectations regarding clinical trial data, our results
of operations, cash needs, financial condition, liquidity,
prospects, future transactions, growth and strategies, the industry
in which we operate, the trends that may affect the industry or us
and the risks uncertainties and other factors described under the
heading "Risk Factors" in Affimed's filings with the Securities and
Exchange Commission. Given these risks, uncertainties and other
factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future.
IR Contact:
Caroline Stewart, Head IRPhone: +1 347394 6793E-Mail:
IR@affimed.com or c.stewart@affimed.com
Media Contact:
Anca Alexandru, Head of Communications, EU IRPhone: +49 6221
64793341E-Mail: a.alexandru@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024